SouthernWorldwide.com – A recent study has indicated that the latest COVID-19 vaccine, specifically the 2024-2025 formulation, may offer an unexpected health advantage by reducing the occurrence of serious heart-related events among U.S. veterans.
The new research has confirmed a modest decrease in cardiovascular events linked to COVID-19, also known as COVID-19-associated MACE (Major Adverse Cardiovascular Events), following vaccination.
MACE is a comprehensive measure that encompasses significant heart-related outcomes. This typically includes fatalities due to cardiovascular causes, heart attacks, strokes, and can also involve hospitalizations for heart failure.
VACCINES FOR FLU AND COVID: SHOULD YOU GET BOTH AT THE SAME TIME?
The study utilized health records from the U.S. Department of Veterans Affairs. Researchers conducted a comparison between two distinct groups of veterans. One group received both the COVID-19 and flu vaccines on the same day, comprising nearly 350,000 individuals. The other group received only the flu vaccine, numbering close to 700,000 people.
The comprehensive analysis involved over one million veterans. The average age of these participants was approximately 70 years, with 92% being male, as detailed in a press release.
Over a period of roughly eight months, the findings revealed that veterans who received the 2024-2025 COVID-19 vaccine experienced a reduced risk of COVID-19-associated major cardiovascular events. The relative vaccine effectiveness in this regard was calculated at 37.7%.
Specifically, the COVID-19 vaccine was associated with a 57.9% lower risk of cardiovascular death. It also showed a 38.5% reduction in the risk of heart attack and a 41.9% decrease in the likelihood of hospitalization for heart failure, according to the researchers. The observed effect on stroke risk did not reach statistical significance.
SCIENTISTS PINPOINT WHY COVID VACCINE MAY TRIGGER HEART INFLAMMATION IN CERTAIN PEOPLE
The study highlighted that the observed cardiovascular benefits were most pronounced in older adults, specifically those aged 75 and above, and individuals with pre-existing health conditions. Among those over 75, the vaccine demonstrated a 50.7% effectiveness in preventing COVID-19-associated MACE.
It is important to note that this study was observational. Therefore, it could not definitively establish a cause-and-effect relationship between the COVID-19 vaccine and the reduced risk of cardiovascular events. Instead, it identified a significant association.
CLICK HERE FOR MORE HEALTH STORIES
“This finding aligns with previous research on COVID-19 vaccines and other vaccines for infectious diseases, which have shown efficacy in preventing cardiovascular events, including heart attacks, cardiovascular deaths, and hospitalizations,” stated a medical expert.
The expert further explained that acute inflammation within the body, often a consequence of infections like COVID-19, elevates the risk of cardiovascular events and can lead to further complications.
“This can result in a higher risk of blood clotting. Additionally, it can make arterial plaques more susceptible to rupture, which then triggers clot formation as the body attempts to heal the ruptured plaque,” the expert elaborated. “This clotting process can lead to a near-total or complete blockage of an artery, ultimately causing these cardiovascular events.”
“Vaccines work by either preventing infection altogether or by mitigating the severity of the infection and the subsequent inflammatory response, thereby reducing the cardiovascular risk.”
Despite these positive findings, Dr. Hirsch, who was not involved in the research, commented that the overall benefit observed in this particular study was less pronounced compared to earlier studies.
He suggested that this could be attributed to several factors. These include the potentially lower severity of illness associated with more recent COVID-19 variants. Furthermore, the existing immunity from prior infections among unvaccinated individuals might also play a role. The decline in COVID-19 testing rates also makes it more challenging to directly link cardiovascular events to the virus.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“In essence, the evidence continues to support the benefits of COVID-19 vaccination, much like many other infectious disease vaccinations. People should be encouraged to discuss these options with their healthcare providers annually,” advised Dr. Hirsch.
“It is crucial to remember that this was an observational trial. While statistical adjustments were made, there is always the potential for confounding factors. Other potential benefits or harms, including vaccine adverse effects that were not examined in this study, cannot be ruled out,” he concluded.
